These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 35284050)
1. Understanding the influence of AMG 510 on the structure of KRAS Li Y; Han L; Zhang Z Comput Struct Biotechnol J; 2022; 20():1056-1067. PubMed ID: 35284050 [TBL] [Abstract][Full Text] [Related]
6. Modeling receptor flexibility in the structure-based design of KRAS Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206 [TBL] [Abstract][Full Text] [Related]
7. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models. Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410 [TBL] [Abstract][Full Text] [Related]
8. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824 [TBL] [Abstract][Full Text] [Related]
9. AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research. Wu LL; Jiang WM; Liu ZY; Zhang YY; Qian JY; Liu Y; Huang YY; Li K; Li ZX; Ma GW; Xie D Discov Oncol; 2023 Jun; 14(1):91. PubMed ID: 37284902 [TBL] [Abstract][Full Text] [Related]
10. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681 [TBL] [Abstract][Full Text] [Related]
11. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS Luo L; Zheng T; Wang Q; Liao Y; Zheng X; Zhong A; Huang Z; Luo H Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631410 [TBL] [Abstract][Full Text] [Related]
13. A Breakthrough Brought about by Targeting KRAS Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550 [TBL] [Abstract][Full Text] [Related]
14. Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS Zhuang H; Fan J; Li M; Zhang H; Yang X; Lin L; Lu S; Wang Q; Liu Y Front Oncol; 2022; 12():915512. PubMed ID: 36033504 [TBL] [Abstract][Full Text] [Related]
15. Nonclinical Safety Profile of Sotorasib, a KRAS Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282 [TBL] [Abstract][Full Text] [Related]
16. Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL. Kitazawa M; Miyagawa Y; Koyama M; Nakamura S; Hondo N; Miyazaki S; Muranaka F; Tokumaru S; Yamamoto Y; Ehara T; Kuroiwa M; Tanaka H; Komatsu D; Takeoka M; Soejima Y Mol Clin Oncol; 2021 Jul; 15(1):148. PubMed ID: 34094546 [TBL] [Abstract][Full Text] [Related]